Sangamo BioSciences | SGMO - Ebit


Sangamo BioSciences reported $-72.22M in EBIT for its fiscal quarter ending in June of 2023.





Ebit Change Date
Alaunos Therapeutics USD -1.01M 175K Mar/2026
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
Amgen USD 3.83B 130M Mar/2026
Bayer EUR 3.53B 2.42B Mar/2026
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
Biogen USD 514.3M 502.8M Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Cipla INR 6.14B 3.63B Mar/2026
Clal Biotechnology ILS -5.44M 3.76M Dec/2022
Compugen USD 56.04M 63.94M Dec/2025
CSL USD 2.64B 116M Dec/2025
Gilead Sciences USD 2.68B 284M Mar/2026
GlaxoSmithKline GBP 2.29B 856M Mar/2026
Grifols EUR 320.55M 91.01M Dec/2025
Ionis Pharmaceuticals USD -118M 97M Mar/2026
J&J USD 6.62B 1.51B Mar/2026
Karyopharm Therapeutics USD -17.84M 8.44M Dec/2025
Merck USD -1.88B 8.12B Mar/2026
Novartis USD 4.18B 118M Mar/2026
Omeros USD -48.15M 7.25M Sep/2023
Pfizer USD 4.99B 340M Mar/2026
Roche Holding CHF 9.56B 2.1B Dec/2025
Sanofi EUR 1.94B 239M Mar/2026
Sarepta Therapeutics USD 358.43M 768.52M Mar/2026
Tectonic Therapeutic USD -21.52M 374K Dec/2025
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
Vertex Pharmaceuticals USD 1.14B 124.5M Mar/2026